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are given chemotherapy or other immuno-
suppressant drugs (including corticoster-
oids). In this syndrome, autoinfective larvae
disseminate in large n mbers from the gas-
trointestinal tract, leading to superimposed
bacterial meningitis and septicaemia; it has
a mortality rate of up to 87%.2
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Objective:  To investigate the first reported cases of strongyloidiasis in the Solomon 
Islands, and to establish whether this disease poses a risk to personnel of the Regional 
Assistance Mission to Solomon Islands (RAMSI).
Design, setting and participants:  Retrospective review of the pathology database 
of the RAMSI Medical Facility in Honiara, Solomon Islands, for the period 1 July 2006 – 
ptember 2007.
 outcome measures:  Number and clinical features of confirmed cases of 
gyloides stercoralis infestation, as diagnosed by serological tests or faecal 
scopy.
lts:  Fourteen confirmed cases of strongyloidiasis in previously healthy RAMSI 
cipants were identified. Of 13 patients with notes available, symptoms documented 
esentation included epigastric pain (10 patients), diarrhoea (7) and urticaria (4). 
Clinical disease in all patients responded to oral antihelminthic therapy (albendazole 
or ivermectin).
Conclusions:  Strongyloidiasis is endemic in the Solomon Islands and a risk for RAMSI 
personnel. Australian medical professionals should be aware of this potentially fatal and 
lifelong infestation, particularly the importance of an occupation history, appropriate 
diagnostic tests, effective treatment and adequate follow-up to document cure. 
We recommend implementation of a postdeployment screening program for 
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atoS ngyloides stercoralis is a soil-trans-tted parasitic gastrointestinal nem-de that can persist for years in the
human intestine through the production of
autoinfective larvae.1 Patients at risk of
strongyloidiasis should be screened to pre-
vent hyperinfection syndrome before they
Although strongyloidiasis occurs in
Papua New Guinea,3 Fiji4 and Vanuatu,5 it
has not been reported in the Solomon
Islands. This may be because faecal micro-
scopy is not routinely performed at the
National Referral Hospital in Honiara, and
serology testing is not available in the
Solomon Islands (Dr Tenneth Dalipanda,
Chief Executive Officer and Medical Super-
intendent, National Referral Hospital, Hon-
i a r a ,  S o lo m o n  I s l a n d s ,  pe r s o n a l
communication).
The only published survey of soil-trans-
mitted helminths in the Solomon Islands
was conducted in a semi-urban environ-
ment, and reported that 40.7%–45% of
children tested were infected with a soil-
transmitted helminth — Ascaris lumbri-
coides, hookworm or Trichuris trichiura.6
Protracted ethnic tensions in the Solo-
mon Islands (1998–2003) resulted in the
establishment of the Regional Assistance
Mission to Solomon Islands (RAMSI).
Member countries of the Pacific Islands
Forum, under Australia’s leadership, estab-
lished RAMSI in 2003 with the aim of
restoring law and order and assisting the
Solomon Islands’ economic recovery. Par-
ticipating nations have sent several thou-
sand military personnel, police officers and
civilian advisers to the Solomon Islands;
most are from Australia and New Zealand.
Until recently, before returning to their
country of origin, RAMSI personnel
received mebendazole, which is ineffective
against S. stercoralis.7
The RAMSI Medical Facility in Honiara
is contracted by the Australian Govern-
ment to provide comprehensive health care
for RAMSI personnel, who are estimated to
number around 1000 at any given time.
At the Medical Facility, we diagnosed
strongyloidiasis in several personnel. This
led to concern for undiagnosed personnel
who return home to non-endemic regions,
where the awareness of the implications of
prior exposure is limited. Prescription of
chemotherapy, corticosteroids or other
immunosuppressive medications without
appropriate screening and treatment in this
cohort would be of particular concern.
Therefore, we undertook a retrospective
review of the RAMSI Medical Facility
pathology database to determine the epi-
demiology of strongyloidiasis in RAMSI
personnel and the need for a postdeploy-
ment screening program.
METHODS
Cases of S. stercoralis infestation were
diagnosed based on faecal microscopy or
serology.
Stool samples were examined via direct
microscopy of faeces concentrate (Mini
Parasep faecal parasite concentration kit;
DiaSys, Wokingham, Berkshire, UK) by an
onsite medical scientist. S. stercoralis can be
differentiated from Strongyloides fuelleborni
(which causes limited disease in humans)
based on the presence of larvae and not
eggs in the faeces.8
Serological tests were performed at the
Queensland Medical Laboratory, Brisbane,
using enzyme-linked immunosorbent assay
(ELISA). Optical density was categorised as
negative (< 0.9 optical density units
[ODU]), equivocal (0.9–1.2 ODU), or posi-
tive (> 1.2 ODU).
We retrospectively reviewed the patho-
logy database of the RAMSI Medical Facil-
ity for the period 1 July 2006 – 30
September 2007. We searched the database
for the results of faecal examinations and
Strongyloides serological tests. The medical
records of patients with positive results
were reviewed, if available.
RESULTS
We found 168 faecal examination results
and 34 Strongyloides serological test results;
some patients had received both tests. We
identified 14 patients with S. stercoralis
infestation: 11 men and three women
(average age, 36 years). Only one patient
was deployed from an area with highJA • Volume 189 Number 4 • 18 August 2008 203
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Asia) (Box 1). S. fuelleborni infestation was
not observed.
Thirteen of the 14 patients had case
notes available for review. Among these,
epigastric pain exacerbated by eating was
the most common symptom (10/13; 77%).
Diarrhoea and urticaria or other skin mani-
festations were reported in 54% (7/13) and
31% (4/13) of individuals, respectively
(Box 1).
Importantly, we found that the symp-
toms of strongyloidiasis were frequently
misinterpreted. Epigastric pain was misdia-
gnosed as gastro-oesophageal reflux, and
was thus treated unsuccessfully with pro-
ton-pump inhibitors. Two patients with
urticarial rash were diagnosed as having
insect bites and were treated with cortico-
steroids. Notably, Patient 1 received 40 mg
methylprednisolone intramuscularly, and
developed lower abdominal pain, back
pain and dysentery 2 days later, which
necessitated hospital admission. Faecal
microscopy revealed S. stercoralis larvae,
and prompt treatment with albendazole led
to resolution of symptoms.
We cannot report detailed follow-up
information due to the limited duration of
deployments and difficulty accessing
patients’ records upon return to their coun-
tries of origin. However, Box 1 details the
treatments given after strongyloidiasis was
diagnosed, and the initial clinical response.
The standard treatments used were oral
albendazole 400 mg twice daily for 3 days
or a single dose of oral ivermectin 200 μg/kg.
DISCUSSION
This retrospective audit identifies the Solo-
mon Islands as an S. stercoralis-endemic
region and RAMSI personnel as being at
risk of infestation.
A strength of this study was the presence
of a facility in the Solomon Islands capable
of performing microscopy and with access
to serological testing. Many of these cases
would not have been diagnosed without
serological testing.
The literature provides limited data on
the symptoms of acute strongyloidiasis.
Our data on presenting symptoms are use-
ful and serve to remind clinicians to con-
sider strongyloidiasis as a differential
diagnosis in all symptomatic returned
RAMSI personnel, particularly those pre-
senting with epigastric pain, diarrhoea or
urticaria. Larva currens — a rapidly pro-
gressing rash caused by migration of the
larvae and pathognomonic of strongyloi-
diasis — was not documented in this case
series. This is consistent with previous
reports that suggest it is rarely seen in acute
infestations.9
Given the nature of the study, and fluctu-
ation in numbers and frequent rotation of
RAMSI personnel, we cannot estimate dis-
ease incidence. However, it is likely that
our audit underestimated the number of
1 Cases of strongyloidiasis in personnel of the Regional Assistance Mission to Solomon Islands: clinical and laboratory 
features, treatment and response
Patient
Age 
(years),
 sex Role
Eosinophils* 
( 109/L)
Strongyloides 
serology 
(ODU)†
Faecal 
microscopy Clinical features Treatment (response)
1 23, F NZDF 0.5 nd + Epigastric pain, skin rash, 
dysentery
Albendazole (SR)
2 36, M TDS 0.6 < 0.9 + Epigastric pain, urticaria Albendazole, ivermectin (SR)
3 40, M NZPF nd nd + Diarrhoea, urticaria Albendazole (SR, faeces − )
4 56, F NZPF nd nd + Epigastric pain, diarrhoea Albendazole, ivermectin (intermittent 
diarrhoea, faeces − , serology 1.0 ODU)
5 52, M AFP nd nd + Diarrhoea Albendazole (SR)
6 31, M AFP < 0.5 nd + Epigastric pain, diarrhoea Albendazole (diarrhoea, faeces − ); 
ivermectin (SR)
7 33, M Civilian 
(SI)
1.0 3.4 − Epigastric pain Albendazole, ivermectin (SR)
8 43, M TPF 2.7 2.4 − Epigastric pain, diarrhoea Untreated (SR, serology 4.8); 
albendazole, ivermectin (SR)
9 53, F Civilian 
(SE Asia)
0.7 4.3 nd Skin rash Ivermectin (SR)
10 46, M Civilian 
(Aust)
3.5 3.5 + Epigastric pain, diarrhoea Ivermectin (SR)
11 25, M NZDF 8.6 1.7 nd Epigastric pain Albendazole, ivermectin 
(SR, eosinophils 0.6  109/L)
12 19, M NZDF 3.3 1.8 nd Epigastric pain Albendazole, ivermectin (SR)
13 22, M NZDF 0.5 1.2 nd Epigastric pain Albendazole, ivermectin 
(SR, serology < 0.9)
14 24, M ADF 6.7 1.5 nd na na
Aust = Australia. ADF = Australian Defence Force. AFP = Australian Federal Police. faeces − = negative result on faecal microscopy. na = history not available. 
nd = not done. − = negative. NZDF = New Zealand Defence Force. NZPF = New Zealand Police Force. ODU = optical density units. + = positive. SE = South-East. 
SI = Solomon Islands. SR = symptom resolution. TDS = Tonga Defence Services. TPF = Tonga Police Force.
* Reference range, < 0.5  109/L. † Reference range, > 1.2 ODU. ◆204 MJA • Volume 189 Number 4 • 18 August 2008
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period because:
• strongyloidiasis can be asymptomatic;10
• symptomatic individuals might have
failed to seek medical attention or been
treated empirically with antihelminthic
therapy;
• some personnel might have developed
symptoms only after leaving the Solomon
Islands; and
• diagnostic tests have significant limitations.
A recent study suggests the Strongyloides
ELISA is significantly less sensitive in
returned travellers (patients with acute
infestation, similar to our cohort) com-
pared with immigrants with previous
c h ro n i c  e x p o s u r e  ( 73 %  v  9 8% ;
P < 0.001).11 Further, the time necessary
for  se rocon vers i on in  h umans  i s
unknown.12 Thus, false-negative results
may be obtained in patients tested before
seroconversion. Faecal microscopy has
low sensitivity in chronic uncomplicated
strongyloidiasis,10 and its sensitivity in
acute strongyloidiasis is not clearly
defined. However, diagnostic accuracy can
be improved by examining multiple stool
samples or using Strongyloides agar-plate
culture.13
It is vital to identify and treat individuals
with strongyloidiasis before immunosup-
pression in order to minimise the risk of
hyperinfection syndrome. Our study high-
lights this, as systemic corticosteroids were
used to treat urticarial skin rash in two of
our 14 patients, with adverse con-
sequences; corticosteroid treatment was also
the precipitant of fatal disseminated strongy-
loidiasis in a case reported in 2001.14
The diagnosis of strongyloidiasis before
immunosuppression requires a high index
of suspicion. As Australian-led interven-
tions in the Asia–Pacific region are likely to
increase, an increasing number of Austral-
ians will be exposed to S. stercoralis. Thus,
it is evident that all patients being consid-
ered for immunosuppressive therapy must
have an occupational history taken. If this
reveals a geographic risk factor for strongy-
loidiasis, appropriate testing and treatment
(if positive) must be instituted before
immunosuppression.
Accordingly, we propose a postdeploy-
ment screening program comprising a full
blood count (to detect eosinophilia),
Strongyloides serology and microscopy, and
agar-plate culture of a stool specimen. The
absence of a “gold-standard” test mandates
the use of a combined diagnostic approach.
These tests could be performed 3 months
after departure from the Solomon Islands,
coinciding with screening for exposure to
bloodborne viruses and tuberculosis to
maximise compliance with follow-up.
Our incomplete follow-up data prevent
assessment of treatment efficacy. However,
ivermectin is currently considered first-line
treatment for uncomplicated S. stercoralis
infestations due to its high efficacy (83%
microscopic clearance after 3 months).15,16
Although albendazole (400 mg twice daily
for 3 days) is less efficacious (75% micro-
scopic clearance after 6 months),17 its
broader antihelminthic activity (especially
against hookworm) makes it more suitable
for empirical treatment.18,19 It has recently
replaced mebendazole as the postdeploy-
ment antihelminthic eradication therapy
used by RAMSI.
Follow-up serological testing to docu-
ment eradication is a necessary part of a
screening program, as strongyloidiasis is
considered a lifelong infestation until
proven eradicated. The case of a Laotian
immigrant to Australia who died from
Strongyloides hyperinfection caused by
inadvertent immunosuppression a year
after treatment with albendazole14 supports
this component of the proposed screening
program (Box 2).
Staff inductions have been changed to
include information about the lifelong
nature of strongyloidiasis infestation and
its potentially fatal complications. RAMSI
personnel are advised to avoid skin expo-
sure to soil that may have been contami-
nated by human faeces, principally by
wearing appropriate footwear. Australian
medical professionals should be aware that
strongyloidiasis is endemic in the Solomon
Islands and that RAMSI personnel are at
risk of infestation. A postdeployment
screening program is recommended for all
RAMSI personnel.
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